login
  Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

Refined balloon pulmonary angioplasty procedure improves the clinical status of CTEPH patients


Friday, 21 Dec 2012 11:37
Hiromi Matsubara
Hiromi Matsubara

Hiroki Mizoguchi, Division of Cardiology, National Hospital Organization Okayama Medical Center, Okayama, Japan, and colleagues have refined balloon pulmonary angioplasty for the treatment of inoperable patients with chronic thromboemobolic pulmonary hypertension (CTEPH).


The study leader Hiromi Matsubara, Department of Clinical Science, National Hospital Organization Okayama Medical Center, Okayama, Japan, commented on the study and said: “Recent progress in medical treatment for pulmonary arterial hypertension has improved the prognosis of the patients with the problem. However, patients with CTEPH have been left behind this progress. There have been no effective therapeutic options, especially for the patients diagnosed as unsuitable for pulmonary endarterectomy.”

Balloon pulmonary angioplasty for the treatment of CTEPH was first reported over 10 years ago therefore the authors aimed to readdress the procedure to maximise its clinical efficacy.

In the study, 68 patients with inoperable CTEPH were enrolled and underwent balloon pulmonary angioplasty. The patients were diagnosed as inoperable because of the location of the thrombi and surgical accessibility, age and comorbidities. All patients were in the World Health Organisation (WHO) functional class III or IV with high pulmonary arterial pressure.

Balloon pulmonary angioplasty procedure

According to the study, 68 patients underwent a total of 255 balloon pulmonary angioplasty sessions in which four (2–8) sessions were performed in each patient and the number of vessels dilated per session was three (1–14). The result of the balloon pulmonary angioplasty sessions was that one patient died after the third session because of right-sided heart failure and of the remaining 67 patients 64 (96%) were in the WHO functional class of I or II after the final session. Overall the mean pulmonary arterial pressure was significantly reduced (p<0.01) according to Mizoguchi and others.

Patients were followed up every six months after balloon pulmonary angioplasty. During follow-up one patient died of pneumonia and the remaining 66 patients are alive with 57 patients undergoing right heart catheterisation after final balloon pulmonary angioplasty. The authors reported that these patients had mean pulmonary arterial pressure of 24.0±5.8mmHg with maintained improved heamodynamics at 1±0.9 years.

The implications of the refined balloon pulmonary angioplasty as a treatment for inoperable CTEPH is that it adds to the weight of evidence which suggests it is an effective therapeutic option.

“With the refined technique, we could maximise the efficacy of balloon pulmonary angioplasty for inoperable patients with CTEPH without increasing complications. Improvements of haemodynamics and clinical function obtained by angioplasty were maintained for at least one year. Overall the outcome of angioplasty was almost comparable to that of endarterectomy,” said Matsubara. “Although there are remaining problems to be resolved such as the risk of reperfusion injury and the existence of a learning curve in performing the procedure, our results open up the prospect of pulmonary angioplasty as a promising therapeutic option for patients with CTEPH,” he added.

“Our refined balloon pulmonary angioplasty procedure improves clinical status and the haemodynamic of inoperable patients with CTEPH, with a low mortality,” concluded Mizoguchi et al.




Add New Comment

Most popular


First drug-eluting balloon approved in USA
Friday, 10 Oct 2014
The FDA has approved the Lutonix drug-eluting balloon for the management of peripheral artery disease. This is the first time that the agency has approved such a device for this indication in the USA. First drug-eluting balloon approved in USA

New deep vein thrombosis guidelines: What you need to know
Thursday, 23 Oct 2014
Suresh Vedantham spoke to Interventional News on the latest from the paper “Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus ... New deep vein thrombosis guidelines: What you need to know

Live from VEITH 2014: SUPERB results show 94% freedom from reintervention with nominal deployment of Supera at three years
Wednesday, 19 Nov 2014
Three-year follow-up results of patients treated with the Supera stent show that nominal deployment or slight compression of the device delivers the best outcomes in terms of durability, and that ... Live from VEITH 2014: SUPERB results show 94% freedom from reintervention with nominal deployment of Supera at three years

Features


Selective transarterial chemo embolization in lung cancer
Wednesday, 19 Nov 2014
Embolization therapy combined with infusion of antineoplastic agents offers considerable improvement of symptoms for patients, with far fewer complications than systemic chemotherapy, writes Shinichi ... Selective transarterial chemo embolization in lung cancer

Multidisciplinary panel recommends early revascularisation of diabetic foot to save legs
Tuesday, 04 Nov 2014
Delays in revascularisation of diabetic foot in the UK directly relate to legs being lost to amputation. Early referral to interventionists is of critical importance and interventional radiologists ... Multidisciplinary panel recommends early revascularisation of diabetic foot to save legs

Profiles


José Ignacio Bilbao Jaureguízar
Wednesday, 08 Oct 2014
“No matter what their future orientation, interventional radiologists involved in interventional ... José Ignacio Bilbao Jaureguízar

Bien Soo Tan
Friday, 16 May 2014
Bien Soo Tan, senior consultant, Department of Diagnostic Radiology, Singapore General Hospital, S... Bien Soo Tan

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions